RFP No.       NIH-NIAID-DAIDS-98-14

Title:        "PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE
              RESEARCH AND DEVELOPMENT"

Issued by:    Toni A. Kuhn
              Contracting Officer
              NIH/NIAID
              Contract Management Branch
              Solar Building, Room 3C07
              6003 Executive Boulevard MSC 7610
              Bethesda, Maryland 20892-7610

DATE ISSUED:  AUGUST 22, 1997

PROPOSAL DATE DUE:   NOVEMBER 3, 1997 4:30 P.M. (EST)

Ladies and Gentlemen:

You are invited to submit a proposal in accordance with the
requirements of this RFP (NIH-NIAID-DAIDS-98-14) entitled
"PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND
DEVELOPMENT." The Government anticipates the award of ONE (1),
FIVE (5) YEAR, cost-reimbursement, completion type contract as
a result of this RFP.

The documents included with this electronic STREAMLINED RFP package
are as follows:

     -   Introduction, Background and Work Statement, dated August
         22, 1997 (Attachment A)

     -   Deliverables and Reporting Requirements, dated August 22,
         1997 (Attachment B)

     -   Evaluation Factors for Award, dated August 22, 1997
         (Attachment C)

     -   Specific RFP Instructions and Provisions (Attachment D)

     -   Applicable RFP References (Attachment E)

In addition to the directory which you are currently in (i.e., the
streamlined RFP), there are five (5) other SUBDIRECTORIES in the
Gopher System (gopher://gopher.nih.gov/11/res/rd-rfp/rfpref.c) which
must be retrieved, in whole or in part, in order to submit a proposal
(the applicable portions are explained in Attachment E).
The SUBDIRECTORIES are:

     STANDARD RFP INSTRUCTIONS AND PROVISIONS
     OPTIONAL RFP INSTRUCTIONS AND PROVISIONS
     FORMS, FORMATS AND ATTACHMENTS
     REPRESENTATIONS AND CERTIFICATIONS
     SAMPLE CONTRACT FORMAT-GENERAL

If you are unable to download any of these documents, please contact
Grace Bruce, Contract Specialist, by phone/fax/internet at the
numbers/addresses listed below.

The attachments/documents listed above represent all the necessary
information required for the submission of a proposal for this
acquisition.  Following proposal submission and review, additional
information will be requested by the Contracting Officer from all
offerors which comprise the COMPETITIVE RANGE.

The BUSINESS and TECHNICAL proposals must be separate from one
another in the proposal package as the peer review panel will only
receive the technical proposal.  The BUSINESS PROPOSAL must be
signed by an authorized official of your organization, and must
contain a detailed breakdown of costs by year, for each cost
category/element; the BASIS for all costs must be explained, but
supporting documentation need NOT be submitted with the proposal
(COST AND PRICING DOCUMENTAION WILL BE REQUESTED AFTER THE COMPETITIVE
RANGE IS ESTABLISHED).  See Standard RFP Instructions and Provisions, 
in the Gopher System (gopher://gopher.nih.gov/11/res/rd-rfp/rfpref.c),
for more detail on the BUSINESS PROPOSAL requirements.

With the Business Proposal, please submit Form NIH-2043, "Proposal
Summary and Data Record," contained in the NIH Gopher System
(gopher://gopher.nih.gov/11/res/rd-rfp/rfpref.c) under the
FORMS, FORMATS, AND ATTACHMENTS.  Note that in addition
to telephone and fax numbers, the INTERNET addresses of both the
Principal Investigator and the responsible business representative are
to be included on the form.

DUE TO THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES CURRENT
BUDGET RESTRICTIONS, IT IS RECOMMENDED THAT ANY PROPOSED ANNUAL INCREASE
IN COSTS FOR INFLATION BE LIMITED TO NO MORE THAN 3% OF TOTAL COSTS PER
YEAR.  FINAL INFLATION INCREASES WILL BE SUBJECT TO THE NEGOTIATION
PROCESS TAKING INTO CONSIDERATION THE MOST CURRENT CONSUMER PRICE INDEX
(CPI).

You are reminded that the "Technical Proposal cover Sheet" must be
completed in full detail and used as the cover sheet for each copy of
your technical proposal.  A copy of this form is contained in the NIH
Gopher System (gopher://gopher.nih.gov/11/res/rd-rfp/rfpref.c) under
the FORMS, FORMATS, AND ATTACHMENTS.  It is important that you list
all professional personnel and organizations named in the proposal who
have any role in the proposed work, including: staff of the primary
organization(offeror), subcontractors, collaborating organizations,
and consultants.  Organizational affiliation(s) must be indicated for
every person named.  You may use additional sheets, as needed,
following the format shown in the Technical Proposal Cover Sheet.
This information will be used to ensure that there will be no conflict
of interest when selecting review committee members.

Your attention is further directed to the "Proposal Intent" form
contained in Attachment D, item 9.  Please complete this form and
return it to this office on or before OCTOBER 14, 1997.  This will
allow us to expedite preparations for the peer review of proposals.

If you intend to submit a proposal in response to this RFP, IT IS
ESSENTIAL THAT YOU IMMEDIATELY NOTIFY MS. GRACE BRUCE, CONTRACT
SPECIALIST, OF THE NIAID CONTRACTING OFFICE AT THE FOLLOWING INTERNET
ADDRESS:

                    gb15w@nih.gov

IF YOU FAIL TO NOTIFY THE CONTRACTING OFFICE OF YOUR INTEREST, YOU WILL
NOT RECEIVE NOTIFICATION OF AMENDMENTS ISSUED TO THE RFP.  HOWEVER, ALL
AMENDMENTS WILL BE POSTED ON THE NIH GOPHER AND THE NIH HOME PAGE.

Funds are NOT presently available for this requirement.  The
Government's obligation under a resulting contract is contingent
upon availability of appropriated funds from which payment for
contract purposes can be made.

The original and twenty-four (24) copies of your technical proposal
and the original and four (4) copies of your business proposal must be
received NO LATER THAN NOVEMBER 3, 1997, AT 4:30 p.m. LOCAL TIME AT
THE ADDRESSES LISTED IN ATTACHMENT D, ITEM 4.

Questions concerning any areas of uncertainty which in your opinion
require clarification or correction, must be furnished in writing to
Ms. Grace Bruce no later than SEPTEMBER 30, 1997, at the
Contract Specialist address located in Attachment D, item 4.
The questions should be marked "Offeror's Questions,
RFP-NIH-NIAID-DAIDS-98-14" (Fax or e-mail communication is
preferred).

If you have any additional questions regarding this RFP, please
contact Ms. Grace Bruce at the internet electronic mail address:
gb15w@nih.gov  or by phone at 301/496-0195, or by fax at 301/402-0972.  Collect calls will NOT be accepted.

Sincerely,

  /s/

Toni A. Kuhn
Chief, AIDS Preclinical Research Contract Section
Contract Management Branch
National Institute of Allergy
  and Infectious Diseases

Attachments:  A - E

*****************************************************************
*****************************************************************
RFP-NIH-NIAID-DAIDS-98-14

STREAMLINED RFP
---------------
ATTACHMENT  A

RFP SECTION C
INTRODUCTION, BACKGROUND AND WORK STATEMENT
(August 22, 1997)

INTRODUCTION
------------

The objective of this contract is to continue to provide a centralized
laboratory for standardized and comparative assessment of
immunological responses induced in primates by immunization with
prototype HIV and/or SIV vaccines.

The demonstration of protection by SIV and HIV vaccines in primates
has led to cautious optimism for development of a protective vaccine
against AIDS.  To translate the findings from primates to an effective
HIV vaccine in humans, it is essential to understand which immune
responses provide protection and against which antigen(s) immunity is
directed.  However, assessment of immune responses in primates is
difficult and requires expertise generally not available at primate
centers, where the best animal resources are located. Standard
protocols for assessment of cell-mediated immune responses are still
being developed.  Analysis of virus neutralization with stocks used
for animal challenge is difficult and assays vary among laboratories.
Analysis of mucosal immune responses in primates is still in the
developmental stage. Furthermore, these assessments are time-consuming
and labor-intensive.  Focusing resources in centralized sites provides
the necessary data to compare the immune responses different vaccines
can produce and to correlate them with protection.

The current contractor for the Primate Immunology Laboratory, Beth
Israel Hospital (N01-AI-35166), evaluates the cellular immune responses
of immunized and infected macaques, with emphasis on CTL assays.  Duke
University, as a subcontractor, conducts assays to assess the level and
breadth of virus neutralizing antibodies generated by immunizations.
The Laboratory has developed sensitive CTL assays in the rhesus macaque
system, using antigen-specific stimulation of effector cells, and has
demonstrated the presence of CD8+ CTLs in monkeys immunized with DNA
vaccines and with some recombinant vector vaccines.  Epitopes in the
HIV envelope recognized by the monkeys have been identified and
sequenced.  Neutralizing antibody assays against a variety of SIVs,
SHIVs, and HIVs have been developed, and the presence of neutralizing
antibodies against the challenge virus has been correlated with
protection from infection in several of the SHIV challenges of animals
immunized with HIV envelope vaccines.

The new Primate Immunology Laboratory contractor will continue to test
humoral and cellular immune responses, and will, additionally,
evaluate the mucosal immune responses of macaques and other primates
vaccinated with various candidate SIV or HIV vaccines.  It will
continue to support studies conducted at NIAID's Simian Vaccine
Evaluation Units (SVEUs), which have over 200 primates in a variety of
vaccine studies. [SVEU contractors are: Advanced BioScience
Laboratories (NO1-AI-65314), Henry M. Jackson Foundation (NO1-AI-
65301), TSI Mason Laboratories (NO1-AI-65303), Tulane University (NO1-
AI-65300), and University of Washington (NO1-AI-65302)].  The
Laboratory will develop and employ assays that are more labor-
intensive and/or complex than those currently undertaken by the SVEUs.
These assays would include, among others, type-specific and cross-
reactive neutralizing and enhancing antibody levels, antibody-
dependent cell cytotoxicity, assays of cell-mediated immunity, such as
T-cell proliferative responses to viral proteins or peptides, and
cytotoxic T cell reactions, including characterization of MHC
restriction, as well as assessment of the activity of anti-viral,
suppressor factors.  The Laboratory will also conduct assays to
measure antibody responses, and perhaps eventually cellular immune
responses, at mucosal surfaces of immunized and infected primates.

The current Primate Immunology Laboratory contract was awarded to
Beth Israel Hospital in 1994 and was scaled to provide support
sufficient for three SVEUs.  As a result of the FY96 recompetition
of the SVEUs, five units were awarded.  In addition, a small contract
supported through an interagency agreement with the National Cancer
Institute provides additional capacity for the conduct of neutralizing
antibody assays, and Master Agreement Orders (funded through NIAID's
Master Agreement Program supported by the Preclinical Research Branch)
provide CTL assays and virus neutralization assays for several vaccine
studies being conducted at non-SVEU contract sites.  This RFP Work
Statement and guidance for preparation of cost proposals reflects these
increased requirements.  

                         WORK STATEMENT

PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND
DEVELOPMENT

Independently, and not as an agent of the Government, the Contractor
shall furnish all the necessary services, qualified personnel,
materials, equipment, and facilities, not otherwise provided by the
Government under the terms of this contract, as needed to provide a
Primate Immunology Laboratory that shall support the evaluation of
prototype AIDS vaccines in primates at several institutions under the
sponsorship of the Division of AIDS, NIAID, NIH.

Specifically, the Contractor shall:

A.  Evaluate and characterize the cellular immune responses of
    nonhuman primates that have been immunized with HIV or SIV
    vaccines or infected with SHIV or SIV.  Assays to be conducted
    shall include, but not be limited to, those described below:

    1.   Perform assays to detect HIV or SIV antigen-specific
         cytotoxic T lymphocytes (CTLs) in nonhuman primates
         immunized with HIV or SIV vaccines.

         [NOTE #1 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 1000 CTL assays
         per year (for 150 monkeys).  Offerors should assume that they
         will mainly conduct assays to detect HIV and SIV env-specific
         and gag-specific CTLs, but that they will be requested, less
         frequently, to conduct assays to detect CTLs directed
         at other viral targets, such as pol and nef]

         a.   Receive/obtain peripheral blood cells from all the animals
              in a vaccine study being conducted at a SVEU site or by
              other investigators, and establish transformed B
              lymphoblastoid cell lines to use as stimulator cells
              and/or target cells in CTL assays.  Freeze a stock of each
              transformed cell line and maintain the transformed B cell
              lines for use in the CTL assays.

         [NOTE #2 TO OFFERORS:  For purposes of preparing a
         cost proposal, Offerors should propose to establish and
         maintain transformed B cell lines for 150 monkeys each
         year.]

         b.   Perform SIV or HIV antigen-specific (as appropriate for the
              vaccine  study) in vitro stimulation and expansion of SIV
              or HIV specific CTL precursors from immunized animals and,
              if required by the study protocol, infected animals.

         c.   Perform assays to detect CTL activity directed against
              SIV or HIV epitopes (as appropriate to the specific study)
              in immunized nonhuman primates, and in nonhuman primates
              after virus challenge (if required by the individual
              protocol), using recombinant virus- infected, peptide
              pulsed, or other appropriate autologous cell targets;
              include appropriate controls in the assays.

         d.   Characterize SIV or HIV antigen-specific CTL activity that
              is detected. Studies to be conducted at the request of the
              Project Officer may include: (1) determination whether the
              CTL effector cells are CD8+ cells or CD4+ cells, (2)
              exclusion of NK (natural killer) and ADCC (antibody-
              dependent complement-mediated cytotoxicity) activity, (3)
              determination that the CTL activity is MHC restricted, (4)
              determination of the CTL precursor frequency by limiting
              dilution analysis, and (5) generation of T cell clones with
              anti-HIV or SIV cytotoxic activity.

         [NOTE #3 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should assume that they will be
         requested to further characterize the CTL activity of 50
         samples per year.]

    2.   Perform in vitro assays to evaluate the ability of CD8+
         lymphocytes from immunized nonhuman primates to reduce or
         inhibit HIV or SHIV virus replication in either autologous CD4
         lymphocytes from the animals in the vaccine studies, or
         appropriate heterologous target lymphocytes; include appropriate
         controls.

         [NOTE #4 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 300 of these
         CD8 suppressor assays per year.]

B.  Perform assays to evaluate and characterize the humoral immune
    responses of animals that have been immunized with HIV or SIV
    vaccines or infected with SHIV or SIV.  Assays to be conducted
    are to include, but not be limited to, the following, and are to
    include appropriate controls:

    1.   For animals that have been immunized with HIV vaccines or
         infected with SHIV:

         a.   Perform ELISA, western blot or other appropriate assays
              to detect the presence of HIV or SIV antibodies.

         b.   Perform assays to determine the ability of sera (or mucosal
              secretions as assays are developed) from animals immunized
              with HIV vaccines, or of sera from infected nonhuman
              primates after SHIV challenge, to neutralize infection of
              cell lines and/or primary cells (PBMC) by the HIV strain
              used for the vaccine.  Determine the ability of the sera
              to neutralize the SHIV made with the envelope gene of the
              homologous (vaccine) HIV, if the appropriate SHIV virus
              stock is available.  Characterize the antibodies, including
              determining the neutralization titer against the vaccine
              (homologous) HIV or SHIV strain.

         [NOTE #5 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 1000 SHIV
         neutralization assays per year and 200 HIV neutralization
         assays per year, using sera from immunized monkeys.]

         c.   Determine the neutralization titer against infection of
              appropriate cell lines and/or PBMC by heterologous
              laboratory strains of HIV or heterologous SHIVs for sera
              (or mucosal secretions) that were determined (above) to
              neutralize the homologous strain of HIV or the SHIV
              containing the envelope gene of the homologous HIV.

         [NOTE #6 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 200 assays
         to determine the ability of the monkey sera to neutralize
         heterologous HIV strains and 200 assays to determine the
         ability of the monkey sera to neutralize  heterologous
         SHIV strains per year.]

         d.   Determine the ability to neutralize infection of appropriate
              cell lines and/or primary PBMC and/or primary macrophages by
              primary, "field" isolates of HIV grown only in primary cells
              for sera (or mucosal secretions) that show the ability to
              neutralize heterologous HIV isolates (above).

         [NOTE #7 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 100 assays
         to determine  the ability of the monkey sera to neutralize
         primary HIV isolates per year.]

    2.   For animals that have been immunized with SIV vaccines or
         infected with SIV:

         a.   Determine the capability of sera (or mucosal secretions)
              from animals immunized with SIV vaccines, or infected with
              SIV, to neutralize infection of cell lines and/or primary
              cells (PBMC) by the SIV strain used for the vaccine.
              Further characterize these antibodies, including determining
              the neutralization titer against the vaccine (homologous)
              SIV strain.

         [NOTE #8 TO OFFERORS:  For purposes of preparing a cost
         proposal, Offerors should propose to conduct 1000 SIV
         neutralization assays per year, assessing sera from immunized
         monkeys.]

         b.   Determine the neutralization titer against infection of
              appropriate cell lines and/or PBMC by a heterologous strain
              or strains of SIV for sera (or mucosal secretions) that were
              determined (above) to neutralize the homologous strain of
              SIV.

         [NOTE #9 TO OFFERORS:  For purposes of
         preparing a cost  proposal, Offerors should propose to
         conduct 200 assays per year to determine the ability of
         the monkey sera to neutralize a heterologous SIV
         strain.]

    3.   Grow appropriate HIV, SHIV, and SIV virus stocks, determine
         the in vitro titer of the stocks, and demonstrate that the
         viruses are able to be neutralized by sera from HIV-infected
         people or SHIV- or SIV-infected monkeys prior to conducting
         neutralization assays with the sera from the vaccine studies.
         Virus stocks to be prepared shall be selected with the approval
         of the Project Officer.

         [NOTE #10 TO OFFERORS:  The SHIV, HIV or
         SIV strain to be used in the neutralization assays will
         be determined by the strain used in the vaccine and the
         strain(s) selected for heterologous challenge.  For
         purposes of preparing a cost  proposal, Offerors should
         assume that stocks of HIV-1IIIB, HIV-1MN, one "primary"
         HIV isolate, stocks of three SHIVs (such as SHIVIIIB,
         SHIVSF2,SHIV-Mn, or SHIV-89.6), and stocks of three
         SIVs (such as SIVmac, SIVmne, SIV-DeltaB670) will be
         made and titered for the in vitro neutralization
         assays.]

C.  Perform assays to evaluate and characterize immune responses at
    mucosal sites in nonhuman primates that have been immunized with HIV
    or SIV vaccines or infected with SHIV or SIV.

    1.   Perform assays to detect and measure HIV-specific or SIV-
         specific antibodies (IgG, IgA, and secretory IgA antibodies) or
         antibody-secreting cells in mucosal secretions such as vaginal
         and rectal swabs/washes and saliva of immunized or infected
         macaques.  Include assays on appropriate negative and positive
         control samples.

    2.   Conduct assays to evaluate functional humoral immune responses
         (such as virus neutralization assays as described in section
         3 above) or functional cellular immune responses (such as CTL
         responses as described in section 1 above) in mucosal
         secretions or mucosal tissues of immunized or infected macaques,
         as appropriate assays are developed or become available.

D.  Develop new or more sensitive assays to detect and evaluate
    humoral and cellular immune responses in immunized animals
    (including, for example, assays to detect T lymphocytes that
    specifically bind peptide-MHC Class I complexes, assays to
    detect nonhuman primate cytokine/chemokine expression, and assays
    to detect mucosal immune responses) in order to maintain the
    capability of providing state-of-the-art assays under this
    contract.  Improve current assays (as needed).

         [NOTE #11 TO OFFERORS:  For purposes of preparing a
         cost proposal, Offerors are requested to discuss
         their experience in improving existing and developing new
         immunological assays, but no additional budgetary
         provisions are necessary.]

E.  Receive, catalog, track, and maintain an inventory of the specimens
    that arrive for evaluation:

    1.   Advise sample suppliers of the most suitable manner for
         shipment of sera, whole blood, cells or other specimens for
         evaluation and arrange for the transfer of these specimens
         from primate laboratories to the Contractor.  All shipments
         shall be coordinated so that activity/viability of specimens
         are not be adversely affected.

    2.   Pick up or arrange for pick up of incoming specimen
         shipments from a specified airport or other contact site in
         a timely manner and assure maintenance of activity and/or
         viability of the specimens by providing the appropriate
         temperature in transit from the airport or other contact
         site to the Contractor's laboratory.

    3.   Receive and catalog specimens arriving for evaluation
         from the primate laboratories.  Maintain documentation on
         file for all incoming specimens, including but not limited
         to:  primate subject identification number, trial site,
         protocol identification number, specimen collection date and
         condition of sample upon arrival.

    4.   Store cataloged, aliquotted specimens under appropriate
         conditions to retain maximum immunological and biological
         activity.

    5.   Maintain specimen tracking and inventory system such that
         specimens can be traced and located from receipt through
         processing and assay analysis.

F.  Manage and report study data:

    1.   Compile and maintain a computerized database of all assay
         results.  Results are to be recorded with designations of type
         of assay, virus and cell type used, study protocol number,
         animal number, specimen collection date, and other information
         requested by the Project Officer.

    2.   Designate a project coordinator to manage the day-to-day conduct
         of the study, to interact with the SVEU laboratories or other
         laboratories providing non-human primate samples from the
         vaccine study or studies, and to provide information on the
         status of the assay results to the Project Officer.

    3.   Report data and results to NIAID or to a designated NIAID
         contractor.  Printouts of data and verbal reports of the status
         of the study are to be provided on an ongoing basis
         during the course of the study at the request of the Project
         Officer, in addition to the required periodic (quarterly
         and final) written reports describing the progress
         of the study.  Data shall be reported in a format approved by
         the Project Officer.

    4.   Meet with Project Officer and attend Scientific Meetings:
         Attend meetings (three per year) with the Project Officer and
         other staff of the Preclinical Research Branch, VPRP, DAIDS,
         NIAID.
  
         [NOTE #12 TO OFFEROR:  For purposes of preparing a cost
         proposal, assume 3 trips a year for the Principal
         Investigator (or designate) and the Co-investigator
         (or designate) to attend the meetings with the Project
         Officer which will be held in the Washington, D.C.
         metropolitan area.  One of these meetings will be at the
         Annual National Cooperative Vaccine Development Group Meeting
         and will include representatives from the SIV VEUs.  The other
         meetings will be held in Bethesda/Rockville.  In addition, for
         purposes of preparing a cost proposal, Offerors should include
         a travel budget for the Principal Investigator and the
         Co-Investigator each to attend one Scientific Meeting a year
         to present results obtained under this contract.]

    5.   Obtain clearance for publication.

         Provide advance copies of draft manuscripts (including abstracts
         and public presentations) resulting from this contract to the
         Project Officer and obtain clearance in writing before
         submitting for publication or presentation.  The Contractor
         shall be bound by the same terms as the Government to respect
         the confidential nature of information provided by the
         preclinical trial investigators and the vaccine product
         developers.  Support from the Government contract shall be
         acknowledged in all abstracts, presentations, and publications.

         [NOTE #13 TO OFFEROR:  An Advance Understanding (See article
         XX) will be inserted in any resultant contract, stating
         that the Contractor agrees that manuscripts based on data
         generated under this contract will not be submitted for
         publication or presentation until written
         concurrence has been received from the Project Officer.]

G.  Provide facilities and resources

    1.   Provide facilities and equipment for the work to be
         conducted, including a biosafety level 2 or 3 laboratory for
         conducting work with live HIV and SHIV as well as samples from
         infected monkeys.

    2.   Provide, maintain, and operate facilities for controlled
         storage of virus stocks, cell stocks, and other samples and
         reagents, including storage at -10 to -20 degrees C, at -70
         to - 90 degrees C, and in liquid nitrogen, with appropriate
         monitoring of storage conditions to guarantee continuous proper
         storage.  The reliability of supply systems, electrical power,
         and backup support systems shall be ensured by the contractor.

    3.   Provide protective garments, equipment and sufficient
         monitoring to assure safe handling of potentially hazardous
         materials, including radioactive materials.  Specifically, the
         contractor shall comply with all applicable health and safety
         regulations while conducting the work set forth herein.

H.  Ensure an orderly transition to a successor Contractor.

    By the end of the fourth year of this contract, the Contractor
    shall refine a plan for and be prepared to implement an orderly
    transition of data and specimens to a successor Contractor or to
    the Government, subject to Project Officer approval, and shall
    deliver, if requested by the Project Officer and by the
    completion date of the Contract, the following items:  Original
    data, reagents, stored specimens, and any necessary information
    related thereto, and Government owned equipment and property.

********************************************************************
********************************************************************
RFP-NIH-NIAID-DAIDS-98-14

ATTACHMENT  B

DELIVERABLES AND REPORTING REQUIREMENTS
(August 22, 1997)

I.  Quarterly Progress Reports

    By the fifteenth working day of the month following the end of
    each quarter, for the first three quarters of the year, the
    Contractor shall submit three (3) copies of a quarterly
    progress report as described below.  Two (2) copies should be
    submitted to the Project Officer and one (1) copy to the
    Contracting Officer.  The quarterly report should be factual
    and concise and consist of the following:

    1)   A title page containing:

         (a)  Contract number and title
         (b)  Sequence of report; e.g., "Year 1, 2nd
              Quarterly Report"
         (c)  Period of performance being reported
         (d)  Contractor's name and address
         (e)  Date of submission

    2)   Reports shall include, but are not limited to the
         following information:

         (a)  A brief introduction covering the objective
              and scope of the contract effort.

         (b)  A description of overall progress plus
              short descriptions of the methodology and reagents
              employed for each immunological or virological assay
              employed during the performance period, specifying
              changes in critical reagents or protocols.

         (c)  Separate tables listing:

              1]   An inventory of
                   specimens received during the performance
                   period, but on which assays have not yet
                   been performed.

              2]   The assays performed
                   during the performance period, indicating
                   number of each performed.

              3]   The specimens on
                   which assays were performed during the
                   performance period.

              4]   An ordered listing and interpretation
                   of results from all immunological assays
                   performed during the performance period.

         (d)  A description of any technical
              or performance problems encountered and
              corrective actions planned or taken.
              An explanation of any differences between planned and
              actual progress.

         (e)  Selected other information as
              may be required by the Project Officer.

    3)   A quarterly report is not due when an
         annual report is due.

II. Annual Report

    On or before the last day of the Contract year, the
    Contractor shall submit three (3) copies of an annual
    report.  Two (2) copies shall be submitted to the
    Project Officer and one (1) copy shall be submitted to
    the Contracting Officer.  The annual report shall
    summarize progress for the entire contract year,
    following the same format as for the quarterly reports,
    and shall take the place of the fourth quarterly report.
    In addition, it shall include abstracts, manuscripts in
    progress or submitted, and publications resulting from
    the performance of work under this contract.  An annual
    report is not required when the final report is due.

III.Final Report

    The contractor shall submit three (3) copies of the
    final report documents, two (2) copies to the Project
    Officer and one (1) copy to the Contracting Officer,
    which shall summarize the results of the entire contract
    work for the complete performance period.  This report
    shall be in sufficient detail to explain comprehensively
    the results achieved and shall be submitted no later
    than the completion date of the Contract.

    The final report shall contain:

    1)   Title Page as described above in
         paragraph I. 1) (a).

    2)   Introduction covering the purpose and
         scope of the contract effort.

    3)   Description of the overall progress, plus
         a separate description of each protocol and type of
         assay employed and its modifications and
         performance on the contract during the period of
         performance.  Descriptions shall include pertinent
         immunological assay data in tables
         or graphs as appropriate to present significant
         results achieved, conclusions resulting from
         analysis, and a scientific evaluation of the data
         accrued under the contract.

    4)   Copies of any abstracts, manuscripts, and
         publications.

IV. Other Deliverables.

    The Contractor, subject to Project Officer approval
    shall deliver to the Government or its designee by 
    the completion date of the contract, the following
    items:

    1)   Stored primate-derived specimens or
         reagents including those received by the 
         Contractor from the Project Officer or designated
         investigators.

    2)   A computer-generated listing of
         accurate and updated information on the
         specimen inventory, including
         activities of the Contractor, computerized
         data files, original data and any necessary
         information related thereto;

    3)   Labeled and inventoried paper
         files; and

    4)   Government-owned equipment and
         property.

V.  If the Contractor becomes unable to deliver the
    reports or other deliverables here specified within the
    period of performance because of unforeseen
    difficulties, notwithstanding the exercise of good faith
    and diligent efforts in performance of the work, the
    Contractor shall give the Contracting Officer immediate
    written notice of anticipated delays with reasons
    therefore at the address given below in section VII.

VI. Copies of the technical reports shall be submitted
    as follows:

    Type of        No. of
    Report         Copies         Addresses:

    Quarterly        2            Project Officer
                                  PRB, VPRP, DAIDS
    Annual           2            NIAID, NIH
    Final            2            Solar Bldg., Rm. 2A33
                                  6003 Executive Blvd., MSC 7620
                                  Bethesda, MD 20892-7620

    Quarterly        1            Contract Specialist
    Annual           1            CMB, DEA, NIAID, NIH
    Final            1            Solar Bldg., Rm. 3C07
                                  6003 Executive Blvd., MSC 7610
                                  Bethesda, MD 20892-7610

********************************************************************
********************************************************************
RFP-NIH-NIAID-DAIDS-98-14

ATTACHMENT  C
(August 22, 1997)

EVALUATION FACTORS FOR AWARD
RFP SECTION M
____________________________

1.  GENERAL

    Selection of an offeror for contract award will be based on an
    evaluation of proposals against two factors.  The factors in order
    of importance are 1) technical and 2) cost.  Although technical
    factors are of paramount consideration in the award of the
    contract, cost or price are also important to the overall contract
    award decision.  All evaluation factors other than cost or price,
    when combined, are significantly more important than cost or
    price.

    Offerors are advised that award will be made to that offeror whose
    proposal provides the best overall value to the Government.
  
    The evaluation will be based on the demonstrated capabilities of
    the prospective contractors in relation to the needs of the project
    as set forth in the RFP.  The merits of each proposal will be
    evaluated carefully.  Each proposal must document the feasibility
    of successful implementation of the requirements of the RFP.
    Offerors must submit information sufficient to evaluate their
    proposals based on the detailed criteria listed below.

    Listed below are mandatory qualification criteria and technical
    evaluation criteria.  The mandatory qualification criteria
    establishes conditions that MUST be met at the time of receipt of
    Best and Final Offers (BAFO) by the Contracting Officer in order
    for your proposal to be considered any further for award.

    The technical evaluation criteria are used by the technical
    evaluation committee when reviewing the technical proposals.  The
    criteria below are listed in the order of relative importance
    with weights assigned for evaluation purposes.  Proposals will be
    judged solely on the written material provided by the Offerors.

2.  MANDATORY QUALIFICATION CRITERIA

    The following mandatory qualification criteria establish
    conditions that MUST be met by the time of submission of the Best
    and Final Offer in order for the proposal to be considered for
    award:

    The Contractor must have available biosafety level 2 or 3
    facilities of sufficient capacity for all laboratory procedures
    and assays employing HIV-1, SIV, or SHIV isolates.

3.  TECHNICAL EVALUATION CRITERIA

    1. PERSONNEL . . . . . . . . . . . . . . . . . . . Total:  60 points

    Documented experience, expertise, and availability of the Principal
    Investigator and other proposed professional and technical staff
    (including any consultants or subcontractors) necessary to perform
    the specified tasks, including experience in the conduct of large
    numbers of the specified assays for multiple collaborations:

       Experience in developing and conducting assays to detect and
       characterize HIV-specific or SIV-specific cellular immune
       responses in nonhuman primates that have been immunized with
       HIV or SIV vaccines or infected with SHIV or SIV, including
       the conduct of assays to detect cytotoxic T cell (CTL)
       activity directed against SIV or HIV proteins or peptides and
       CD8 suppressor cell activity that inhibits SIV, SHIV, or HIV
       replication in CD4+ lymphocytes.

       Experience in developing and conducting assays to detect and
       characterize the humoral immune responses of animals immunized
       with HIV or SIV vaccines or infected with SHIV or SIV,
       including the conduct of ELISA and western blot assays to detect
       the presence of HIV- or SIV-specific antibodies, and assays to
       detect and determine the titer of neutralizing antibodies
       directed against SHIV, HIV, or SIV.

       Experience in developing and conducting assays to detect and
       characterize immune responses at mucosal surfaces or in mucosal
       secretions of nonhuman primates immunized with HIV or SIV
       vaccines or infected with SHIV, SIV, or HIV.

       Experience of the Principal Investigator in the management,
       administration, and coordination of a comparable technical effort
       to the one being requested, i.e., a laboratory that has conducted
       a large number of assays in collaboration with multiple
       investigators.

       Relevant experience of person(s) designated to manage the
       computer databases.

    2.   TECHNICAL APPROACH/METHODOLOGY . . . . . . .  Total: 30 points

    Appropriateness of the proposed technical approaches and
    methodologies to be used to conduct the specified tasks.
    Completeness of description of the proposed methodologies and
    thoroughness of discussion of potential problems and appropriate
    controls and alternate approaches to be used to conduct the
    proposed tasks:

       Detection and characterization of cellular immune responses
       of nonhuman primates that have been immunized with HIV or SIV
       vaccines or infected with SHIV or SIV, including assays to
       detect and characterize CTLs to SIV and/or HIV proteins or
       peptides and to assess CD8 suppressor cell activity in
       the immunized animals.

       Detection and characterization of humoral immune responses of
       animals that have been immunized with HIV or SIV vaccines or
       infected with SHIV or SIV, including assays such as ELISA and
       western blot assays to detect HIV- and SIV-specific antibodies,
       assays to detect neutralizing antibody activity directed against
       HIV (both "lab strains" and "primary strains"), SHIV, and SIV,
       and the preparation and characterization of HIV, SHIV, and SIV
       virus stocks for use in neutralization assays.

       Detection and characterization of immune responses at mucosal
       surfaces or in mucosal secretions of nonhuman primates
       immunized with HIV or SIV vaccines or infected with SHIV or
       SIV, including assays to detect HIV- and SIV-specific
       IgG, IgA, and proposed assays to detect HIV- and SIV-
       specific cellular immune responses.

       Acquisition, storage, and management of specimens received from
       vaccine studies for assays.  Tabulation of assay results and
       maintenance of computer data base of data from assays.

3.  RESOURCES AND FACILITIES . . . . . . . . . . . .   Total: 10 points

    Documented availability of laboratory facilities, resources, and
    equipment necessary to conduct the specified tasks, including
    appropriate biocontainment laboratory facilities for conducting
    work with live, infectious SIV, SHIV, or HIV.  Documented
    availability of adequate computer resources for data reporting.

                                                       TOTAL:100 points

********************************************************************
********************************************************************
RFP-NIH-NIAID-DAIDS-98-14

ATTACHMENT D

SPECIFIC RFP INSTRUCTIONS AND PROVISIONS
----------------------------------------

NOTICE TO OFFERORS:  This attachment contains proposal instructions
and information which are specifically related to this acquisition.
The information provided below is only a portion of the instructions
and notices required for the submission of a proposal.  References
to additional, more general, information and forms regarding
proposal preparation are contained in Attachment E, "Applicable RFP
References."

1.  SIC CODE AND SMALL BUSINESS SIZE STANDARD (NIH 3150) (JAN 1997)

Note:  The following information is to be used by the offeror in
preparing its Representations and Certifications (See Attachment E, item 4 
of this RFP), specifically in completing the provision entitled, SMALL
BUSINESS PROGRAM REPRESENTATIONS (JAN 1997), FAR 52.219-1:

(a) The standard industrial classification (SIC) code for this
    acquisition is 8733.

(b) (1)  The small business size standard is $5 million.
    (2)  The small business size standard for a concern which submits
         an offer in its own name, other than on a construction or
         service contract, but which proposes to furnish a product 
         which it did not itself manufacture, is $5 million.

(c) This requirement is NOT set-aside for Small Business.  However, the
    Federal Acquisition Regulation (FAR) requires in every solicitation
    (except for foreign acquisitions) the inclusion of the Standard
    Industrial Classification (SIC) Code and corresponding size standard
    which best describes the nature of the requirement in the
    solicitation.
 
2.  NUMBER AND TYPE OF AWARD(S) (NIH 2980) (APR 1984)

It is anticipated that one (1) award will be made from this
solicitation and that award will be made on or about June 30, 1998.

It is anticipated that the award from this solicitation will be
multiple-year cost reimbursement, completion type contract with a
period of performance of 5 years, and that incremental funding will
be used [see paragraph (6) of Business Proposal Instructions, in the
"Standard RFP Instructions and Provisions" of the Gopher RFP].

3.  ESTIMATE OF EFFORT (NIH 2985) (APR 1984)

It is expected that a completion type contract will be awarded
as a result of this RFP.  To assist you in the preparation of your
proposal, the Government considers the total effort to perform this
contract to be approximately 7,050% (1,410%/year).  This estimate is
furnished for your information only and is not to be considered
restrictive for proposal purposes.  As further assistance, it is
estimated that the above total labor effort is constituted as
follows:

                                Labor Effort*

    Category            Percent Effort/Yr.  x   5 Years  =     TOTAL
    --------            ------------------                     -----
Professional Staff:
    P.I.                       15%                               75%
    Co-Investigators           45%                              225%
    Other Professional Staff  450%                            2,250%
Support Staff:
    Technical Staff           900%                            4,500%
                              ----                            ------
TOTAL                       1,410%                            7,050%

       * Effort in the above chart was based on 100% effort (1 full-time
         equivalent = 2,080 hours per year), which includes holidays and
         other paid absences.  If you are using a different base, please
         state the work year used in your proposal.  The above labor
         effort is the Government's estimate of what will be necessary
         to satisfactorily accomplish the objective(s) of this requirement
         and will be used as a basis for negotiations.  Please provide
         rationale if you propose deviations from this estimated labor
         effort.

4.  PACKAGING AND DELIVERY OF THE PROPOSAL (NIH 2995) (JUL 1994)

    Shipment and marking shall be as indicated below:

    External Package Marking:
    -------------------------

    In addition to the address cited below, mark each package as
    follows:

         "RFP No. NIH-NIAID-DAIDS-98-14"

         "TO BE OPENED BY AUTHORIZED GOVERNMENT PERSONNEL ONLY"

    Number of Copies:
    -----------------

    PLEASE NOTE - THE TECHNICAL PROPOSAL SHALL BE SENT IN SPLIT
    SHIPMENTS TO TWO LOCATIONS.  PLEASE READ THE FOLLOWING
    INFORMATION CAREFULLY:

    A.   TECHNICAL PROPOSAL ONLY

         ORIGINAL* AND 4 COPIES TO:
 
         If hand delivered or delivery service:
         --------------------------------------

         Contract Specialist
         Contract Management Branch
         DEA, NIAID, NIH
         Solar Building, Room 3C07
         6003 Executive Boulevard
         Rockville, Maryland   20852

         If using U.S. Postal Service:
         ----------------------------

         Contract Specialist
         Contract Management Branch
         DEA, NIAID, NIH
         Solar Building, Room 3C07
         6003 Executive Boulevard MSC 7610
         Bethesda, Maryland   20892-7610

        
         20 COPIES TO:

         If hand delivered or delivery service:
         --------------------------------------

         SCIENTIFIC REVIEW PROGRAM
         (Review Processing Unit)
         DEA, NIAID, NIH
         Solar Building, Room 4C15
         6003 Executive Boulevard
         Rockville, Maryland  20852

         If using U.S. Postal Service:
         -----------------------------

         SCIENTIFIC REVIEW PROGRAM
         (Review Processing Unit)
         DEA, NIAID, NIH
         Solar Building, Room 4C15
         6003 Executive Boulevard MSC 7610
         Bethesda, Maryland  20892-7610

    B.   BUSINESS PROPOSAL

         ORIGINAL* AND 4 COPIES TO:

         If hand delivered or delivery service:
         --------------------------------------

         Contract Specialist
         Contract Management Branch
         DEA, NIAID, NIH
         Solar Building, Room 3C07
         6003 Executive Boulevard
         Rockville, Maryland  20852

         If using U.S. Postal Service:
         -----------------------------

         Contract Specialist
         Contract Management Branch
         DEA, NIAID, NIH
         Solar Building, Room 3C07
         6003 Executive Boulevard  MSC 7610
         Bethesda, Maryland  20892-7610
        
    *    THE ORIGINALS MUST BE READILY ACCESSIBLE FOR DATE STAMPING
         PURPOSES

NOTE:  The U.S. Postal Service's "Express Mail" does not deliver to
the Rockville, Maryland address.  Any package sent to the Rockville
address via this service will be held at a local post office for
pick-up.  THE GOVERNMENT IS NOT RESPONSIBLE FOR PICKING UP ANY MAIL
AT A LOCAL POST OFFICE.  If a proposal is not received at the place,
date, and time specified herein, it will be considered a "late
proposal" and handled in accordance with PHSAR 352.215-10 LATE
PROPOSALS, MODIFICATIONS OF PROPOSALS AND WITHDRAWALS OF PROPOSALS
(NOV 1986).

5.  GOVERNMENT NOTICE FOR HANDLING PROPOSALS

    An Offeror shall place this notice on the top of each copy of its
    technical proposal.

    "This proposal shall be used and disclosed for evaluation
    purposes only, and a copy of this Government notice shall be
    applied to any reproduction or abstract thereof.  Any
    authorized restrictive notices which the submitter places on
    this proposal shall also be strictly complied with.  Disclosure
    of this proposal outside the Government for evaluation purposes
    shall be made only to the extent authorized by, and in
    accordance with, the procedures in HHSAR paragraph 315.608-72."

(For information regarding authorized restrictive notices, offerors
should refer to the "Confidentiality of Proposals" section of the
STANDARD RFP INSTRUCTIONS AND PROVISIONS subdirectory of the RFP
REFERENCES directory of the Gopher RFP).

6.  52.233-2  SERVICE OF PROTEST (NOV 1988)

(a) Protests, as defined in Section 33.101 of the Federal
    Acquisition Regulation, that are filed directly with an agency, and
    copies of any protests that are filed with the General Accounting
    Office (GAO) or the General Services Administration Board of
    Contract Appeals (GSBCA), shall be served on the Contracting Officer
    (addressed as follows) by obtaining written and dated
    acknowledgment of receipt from:

         Mr. Lewis Pollack

         Hand-Carried Address:
         --------------------
 
         NIH/NIAID
         Contract Management Branch
         Solar Building, Room 3C07
         6003 Executive Boulevard
         Rockville, Maryland  20852

         Mailing Address:
         ----------------

         NIH/NIAID
         Contract Management Branch
         Solar Building, Room 3C07
         6003 Executive Boulevard MSC 7610
         Bethesda, Maryland   20892-7610

(b) The copy of any protest shall be received in the office
    designated above on the same day a protest is filed with the GSBCA
    or within one day of filing a protest with the GAO.

7.  PHS 352.223-70 SAFETY AND HEALTH

(a) In order to help ensure the protection of the life and health
    of all persons, as well as to help prevent damage to property,
    the Contractor shall comply with all Federal, State, and local
    laws and regulations applicable to the work being performed
    under the contract.  These laws are implemented and/or enforced
    by the Environmental Protection Agency, Occupational Safety and
    Health Administration, and other agencies at the Federal,
    State, and local levels (Federal, State, and local
    regulatory/enforcement agencies).

(b) Further, the Contractor shall take or cause to be taken such
    additional safety measures as the Contracting Officer, in
    conjunction with the project or other appropriate officers,
    determines to be reasonably necessary.  If compliance with such
    additional safety measures results in an increase or decrease
    in the cost or time required of performance of any part of work
    under this contract, an equitable adjustment will be made in
    accordance with whichever applicable "Changes" Clause as set
    forth in this contract (FAR 52.243-1, Changes-Fixed Price; FAR
    52.243-2, Changes-Cost-Reimbursement; or FAR 52.243-3,
    Changes-Time and Materials or Labor-Hours).

(c) The Contractor shall maintain an accurate record of, and
    promptly report to the Contracting Officer, all accidents or
    incidents resulting in the exposure of persons to toxic
    substances, hazardous materials or hazardous operations; the
    injury or death of any person; and/or damage to property
    incidental to work performed under the contact and all
    violations for which the Contractor has been cited by any
    Federal, State, or local regulatory/enforcement agency.  The
    report shall include a copy of the notice of violation and the
    findings of any inquiry or inspection, and an analysis
    addressing the impact these violations may have on the work
    remaining to be performed.  The report shall also state the
    required action(s), if any, to be taken to correct any
    violation(s) noted by the Federal, State, or local
    regulatory/enforcement agency and the time frame allowed by the
    agency to accomplish the necessary corrective action.

(d) If the Contractor fails or refuses to comply promptly with the
    Federal, State, or local regulatory/enforcement agency's
    directive(s) regarding any violation(s) and prescribed
    corrective action(s), the Contracting Officer may issue an
    order stopping all or part of the work until satisfactory
    corrective action (as approved by the Federal, State, or local
    regulatory/enforcement agencies) has been taken and documented
    to the Contracting Officer.  No part of the time lost due to
    any such stop work order shall be subject to a claim for
    extension of time or costs or damages by the Contractor.

(e) The Contractor shall insert the substance of this clause in
    each subcontract involving toxic substances, hazardous
    materials, or hazardous operations.  Compliance with the
    provisions of this clause by subcontractors will be the
    responsibility of the Contractor.

8.  52.227-6   ROYALTY INFORMATION  (APR 1984)

(a) Cost or charges for royalties.  When the response to this
    solicitation contains costs or charges for royalties totaling more
    than $250, the following information shall be included in the
    response relating to each separate item of royalty or license fee:

         (1) Name and address of licensor.

         (2) Date of license agreement.

         (3) Patent numbers, patent application serial numbers,
             or other basis on which the royalty is payable.

         (4) Brief description, including any part or model
             numbers of each contract item or component on which
             the royalty is payable.

         (5) Percentage or dollar rate of royalty per unit.

         (6) Unit price of contract item.

         (7) Number of units.

         (8) Total dollar amount of royalties.

(b) Copies of current licenses.  In addition, if specifically
    requested by the Contracting Officer before execution of the
    contract, the offeror shall furnish a copy of the current license
    agreement and an identification of applicable claims of specific
    patents.

9.  PROPOSAL INTENT RESPONSE SHEET

PROPOSAL INTENT
---------------

RFP No.: NIH-NIAID-DAIDS-98-14

PLEASE REVIEW THE ATTACHED REQUEST FOR PROPOSAL.  FURNISH THE
INFORMATION REQUESTED BELOW AND RETURN THIS PAGE BY OCTOBER 14, 1997.
YOUR EXPRESSION OF INTENT IS NOT BINDING BUT WILL GREATLY ASSIST US
IN PLANNING FOR PROPOSAL EVALUATION.
================================================================

[ ] DO INTEND TO SUBMIT A PROPOSAL FOR THE FOLLOWING:

    __________________________________________________________

    __________________________________________________________

[ ] DO NOT INTEND TO SUBMIT A PROPOSAL FOR THE FOLLOWING
    REASONS:

    __________________________________________________________

    __________________________________________________________

TYPED NAME AND TITLE: _______________________________

INSTITUTION: ________________________________________

SIGNATURE: __________________________________________

TELEPHONE NO.: ______________________________________

DATE: _______________________________________________

-  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -

COLLABORATORS/CONSULTANTS - Provide name(s) and institution(s):

________________________________________________________________

________________________________________________________________

________________________________________________________________
(Continue list on reverse if necessary)

RETURN TO:    CMB, NIAID, NIH
              Solar Building, Room 3C07
              6003 Executive Boulevard MSC 7610
              Bethesda, Maryland  20892-7610
              Attn:  Grace Bruce
              RFP NIH-NIAID-DAIDS-98-14
              Fax# 301/402-0972

PLEASE RETURN BY:  OCTOBER 14, 1997

<End form - Proposal Intent / />************************************************************
********************************************************************

RFP-NIH-NIAID-DAIDS-98-14

ATTACHMENT E

APPLICABLE RFP REFERENCES
------------------------------

This section identifies the items located in the Gopher directory
(gopher://gopher.nih.gov/11/res/rd-rfp/rfpref.c) that are applicable to
this RFP.

1.  The entire file entitled "STANDARD RFP INSTRUCTIONS AND
    PROVISIONS" is applicable to this RFP, except as otherwise may be
    modified by the inclusion of an item from the "OPTIONAL RFP
    INSTRUCTIONS AND PROVISIONS" (below).

2.  The following items are applicable from the file entitled
    "OPTIONAL RFP INSTRUCTIONS AND PROVISIONS":

    -  LATE PROPOSALS, MODIFICATIONS OF PROPOSAL, AND WITHDRAWALS  OF
       PROPOSALS, PHS 352.215-10

    -  SMALL, SMALL DISADVANTAGED AND WOMEN-OWNED SMALL BUSINESS
       SUBCONTRACTING PLAN, FAR 52.219-9  [NOTE: A Subcontracting Plan
       is not due with the initial proposal.  The Contracting Officer
       will notify offerors if a plan becomes due.]

    -  INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN
       SUBJECTS

3.  The following items are applicable from the subdirectory
    entitled "FORMS, FORMATS, AND ATTACHMENTS":

    APPLICABLE TO TECHNICAL PROPOSAL
    --------------------------------

    (1) Technical Proposal Cover Sheet
    (2) Technical Proposal Cost Information, Dec 1988
    (3) Summary of Current and Proposed Activities, July 1995

    APPLICABLE TO BUSINESS PROPOSAL
    -------------------------------

    (4) Contract Pricing Proposal, SF-1411, (Rev. 10/95)
    (5) Proposal Summary and Data record, NIH-2043 (Rev. 6/82)
    (6) Business Proposal Cost Information
    (7) Disclosure of Lobbying Activities, OMB SF-LLL

    TO BECOME CONTRACT ATTACHMENTS
    ------------------------------

    (8) Invoice/Financing Requests Instructions for NIH Cost-
        Reimbursement Type Contracts, NIH(RC)-1, JUN 1992
    (9) Instructions for Completing Form NIH 2706 (Financial
        Report
   (10) Procurement of Certain Equipment, NIH(RC)-7
   (11) NIH Women and Minority Policy
   
   OTHER - TO BE SUBMITTED AS DIRECTED BY CONTRACTING OFFICER
   ----------------------------------------------------------

   (12) Certificate of Current Cost or Pricing Data, NIH-1397
   (13) Subcontracting Plan

4.  The Representations and Certifications are applicable and a
    completed copy must be submitted with offeror's business proposal.

5.  The "Sample Contract Format-General" is applicable.

******************************************************************
End of document